Lyra Therapeutics (LYRA) Stock Price, News & Analysis

Company Overview

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Key Stats

• Today's Range: $0.17 to $0.20
• 50-Day Range: $0.17 to $0.28
• 52-Week Range: $0.16 to $6.79
• Volume: 6.65 million shs
• Average Volume: 1.72 million shs
• Market Capitalization: $11.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.50
• Consensus Rating: Hold

Lyra Therapeutics Stock Analysis - MarketRank™

Lyra Therapeutics scored higher than 67% of companies evaluated by MarketBeat, and ranked 419th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Lyra Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 4 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Lyra Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lyra Therapeutics are expected to grow in the coming year, from ($1.05) to ($0.57) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lyra Therapeutics is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lyra Therapeutics is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lyra Therapeutics has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.12% of the outstanding shares of Lyra Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Lyra Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lyra Therapeutics has recently decreased by 4.67%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lyra Therapeutics does not currently pay a dividend.

Dividend Growth

Lyra Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.12% of the outstanding shares of Lyra Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Lyra Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lyra Therapeutics has recently decreased by 4.67%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.65

News Sentiment

Lyra Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Lyra Therapeutics this week, compared to 1 article on an average week.

Search Interest

10 people have searched for LYRA on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.

MarketBeat Follows

2 people have added Lyra Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lyra Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.69% of the stock of Lyra Therapeutics is held by insiders.

Percentage Held by Institutions

95.62% of the stock of Lyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LYRA Stock Analysis - Frequently Asked Questions

How have LYRA shares performed this year?

Lyra Therapeutics' stock was trading at $5.24 on January 1st, 2024. Since then, LYRA stock has decreased by 96.6% and is now trading at $0.1780.
View the best growth stocks for 2024 here.

How were Lyra Therapeutics' earnings last quarter?

Lyra Therapeutics, Inc. (NASDAQ:LYRA) announced its earnings results on Tuesday, November, 9th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.78) by $0.07. The firm had revenue of $0.01 million for the quarter. Lyra Therapeutics had a negative net margin of 6,635.76% and a negative trailing twelve-month return on equity of 125.07%.

When did Lyra Therapeutics IPO?

Lyra Therapeutics (LYRA) raised $52 million in an IPO on Friday, May 1st 2020. The company issued 3,500,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair acted as the underwriters for the IPO and BTIG was co-manager.

Who are Lyra Therapeutics' major shareholders?

Top institutional shareholders of Lyra Therapeutics include State Street Corp (0.75%). Insiders that own company stock include Perceptive Advisors Llc, Nbvm Gp, Llc, Harlan Waksal, Edward T Anderson and C Ann Merrifield.
View institutional ownership trends.

How do I buy shares of Lyra Therapeutics?

Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Lyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lyra Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), ServiceNow (NOW) and Adobe (ADBE).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/20/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:LYRA
• CUSIP: N/A
• CIK: 1327273
• Web: www.lyratherapeutics.com
• Phone: 617-393-4600
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.50
• High Stock Price Target: $11.00
• Low Stock Price Target: $0.50
• Potential Upside/Downside: +2,428.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-62,680,000.00
• Net Margins: -6,635.76%
• Pretax Margin: -6,632.36%
• Return on Equity: -125.07%
• Return on Assets: -59.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.64
• Quick Ratio: 3.64

Sales & Book Value

• Annual Sales: $1.56 million
• Price / Sales: 7.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.56 per share
• Price / Book: 0.11

Miscellaneous

• Outstanding Shares: 65,460,000
• Free Float: 62,388,000
• Market Cap: $11.65 million
• Optionable: Optionable
• Beta: -0.04